CIBC Private Wealth Group LLC lowered its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,437 shares of the medical equipment provider’s stock after selling 5,000 shares during the period. CIBC Private Wealth Group LLC owned approximately 0.22% of BioLife Solutions worth $1,737,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its holdings in shares of BioLife Solutions by 439.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 1,230 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of BioLife Solutions in the first quarter valued at $36,000. Lazard Asset Management LLC purchased a new stake in shares of BioLife Solutions in the first quarter valued at $45,000. Ancora Advisors LLC purchased a new stake in shares of BioLife Solutions during the first quarter worth $90,000. Finally, Captrust Financial Advisors raised its holdings in shares of BioLife Solutions by 714.2% during the second quarter. Captrust Financial Advisors now owns 3,949 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 3,464 shares in the last quarter. Hedge funds and other institutional investors own 89.82% of the company’s stock.
Insider Buying and Selling at BioLife Solutions
In other news, CEO Michael Rice sold 1,679 shares of the firm’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $23.21, for a total value of $38,969.59. Following the sale, the chief executive officer now directly owns 419,789 shares of the company’s stock, valued at $9,743,302.69. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Michael Rice sold 1,679 shares of the firm’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $23.21, for a total value of $38,969.59. Following the sale, the chief executive officer now directly owns 419,789 shares of the company’s stock, valued at $9,743,302.69. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Troy Wichterman sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $20.64, for a total value of $206,400.00. Following the completion of the sale, the chief financial officer now directly owns 68,160 shares in the company, valued at $1,406,822.40. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 69,973 shares of company stock worth $1,501,560 and have sold 91,259 shares worth $1,912,682. Corporate insiders own 3.30% of the company’s stock.
Wall Street Analysts Forecast Growth
BioLife Solutions Price Performance
NASDAQ BLFS opened at $23.20 on Monday. BioLife Solutions, Inc. has a fifty-two week low of $12.60 and a fifty-two week high of $26.96. The stock’s 50-day moving average is $20.24 and its two-hundred day moving average is $21.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.93 and a current ratio of 2.81.
BioLife Solutions (NASDAQ:BLFS – Get Rating) last posted its earnings results on Thursday, March 16th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). BioLife Solutions had a negative net margin of 89.08% and a negative return on equity of 8.20%. The company had revenue of $44.26 million for the quarter, compared to the consensus estimate of $43.34 million. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.41 EPS for the current year.
BioLife Solutions Profile
BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.
Read More
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- Will Nvidia Be the Lifeline Intel Desperately Needs?
- Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
